Federal Circuit Affirms Aventis' Inequitable Conduct

Law360, New York (May 14, 2008, 12:00 AM EDT) -- A federal appeals court has affirmed a lower court ruling that found Sanofi-Aventis’ patents for its anti-clotting drug Lovenox invalid due to inequitable conduct, allowing generic versions of the drug to make their way toward the U.S. market.

In a 2-1 decision Wednesday, the U.S. Court of Appeals for the Federal Circuit upheld a district court’s February 2007 decision in favor of generics makers Amphastar Pharmaceuticals Inc. and Teva Pharmaceuticals USA Inc., which Sanofi-Aventis subsidiaries Aventis Pharma SA and Aventis Pharmaceutical Inc. had sued for patent...
To view the full article, register now.